Conjunctivitis, Bacterial clinical trials

The registry lists 39 studies for Conjunctivitis, Bacterial across more than 10 countries. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-06-30.

Studies

Recruiting first, then most recently updated. Showing 39 of 39 — search for more.

• Safety and Efficacy of SUM-191 for Patients With Bacterial ConjunctivitisRecruitingNCT07565103Phase 1/21 country
• Efficacy of Fusidic Acid 1% in the Treatment of Bacterial ConjunctivitisRecruitingNCT06911424Phase 31 country
• Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy SubjectsCompletedNCT06363292Phase 11 country
• Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial ConjunctivitisCompletedNCT02432807Phase 31 country
• Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in AdultsCompletedNCT06616922Phase 24 countries
• Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.TerminatedNCT03696342Phase 31 country
• Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and PlaceboCompletedNCT03004924Phase 313 countries
• Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking OphthalmologistsCompletedNCT03987178Not applicable1 country
• Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy SubjectsCompletedNCT03519516Phase 11 country
• Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)CompletedNCT02980523Phase 21 country
• A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial ConjunctivitisCompletedNCT00518089Phase 32 countries
• Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.WithdrawnNCT03698045Phase 11 country
• Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial ConjunctivitisCompletedNCT00759148Phase 3
• Local Pharmacokinetics of Azithromycin Eye Drops in Healthy VolunteersStatus unknownNCT03235141Phase 11 country
• AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00332293Phase 31 country
• Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial ConjunctivitisCompletedNCT01877694Phase 21 country
• An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese PatientsCompletedNCT01573910Phase 31 country
• A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial ConjunctivitisCompletedNCT00348348Phase 3
• A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.CompletedNCT00347932Phase 3
• Clinical and Microbial Efficacy of ISV403 in Bacterial ConjunctivitisCompletedNCT00622908Phase 2
• Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and InfectionWithdrawnNCT01721694Phase 31 country
• Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.CompletedNCT01155999Phase 31 country
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial ConjunctivitisTerminatedNCT01740388Phase 31 country
• Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial ConjunctivitisTerminatedNCT01330355Phase 31 country
• Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)CompletedNCT00105469Phase 31 country
• Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)CompletedNCT00105534Phase 31 country
• Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to VehicleCompletedNCT01175590Phase 31 country
• Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial FloraCompletedNCT00312338Phase 41 country
• Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisCompletedNCT00972777Phase 2/31 country
• Systemic Pharmacokinetics of BOL-303224-ACompletedNCT00407589Phase 11 country
• Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial ConjunctivitisWithdrawnNCT01238783Phase 2
• A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial ConjunctivitisCompletedNCT00509873Phase 31 country
• A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial ConjunctivitisCompletedNCT00464438Phase 42 countries
• Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial ConjunctivitisStatus unknownNCT01227863Phase 31 country
• Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial ConjunctivitisStatus unknownNCT01227915Phase 31 country
• Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic TreatmentCompletedNCT00798577Phase 41 country
• AL-15469A for the Treatment of Bacterial ConjunctivitisCompletedNCT00331916Phase 31 country
• Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial ConjunctivitisCompletedNCT00565123Phase 2/31 country
• Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial ConjunctivitisCompletedNCT00357773Phase 3